457 related articles for article (PubMed ID: 26611557)
1. Infection Risk and Safety of Corticosteroid Use.
Youssef J; Novosad SA; Winthrop KL
Rheum Dis Clin North Am; 2016 Feb; 42(1):157-76, ix-x. PubMed ID: 26611557
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic Infections in Biological Therapy, Risk and Prevention.
Bryant PA; Baddley JW
Rheum Dis Clin North Am; 2017 Feb; 43(1):27-41. PubMed ID: 27890172
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
4. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases.
Malpica L; Moll S
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):319-327. PubMed ID: 33275674
[TBL] [Abstract][Full Text] [Related]
5. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
7. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.
Cooley L; Dendle C; Wolf J; Teh BW; Chen SC; Boutlis C; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1350-63. PubMed ID: 25482745
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of interferon-gamma release assay (T-SPOT.TB(™) ) for diagnosis of tuberculosis infection in rheumatic disease patients.
Jiang B; Ding H; Zhou L; Chen X; Chen S; Bao C
Int J Rheum Dis; 2016 Jan; 19(1):38-42. PubMed ID: 26820838
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of infections in immune deficiency].
Lange B; Neumann S; Hirsch HH; Kern WV
Dtsch Med Wochenschr; 2014 Oct; 139(40):1999-2002. PubMed ID: 25254394
[No Abstract] [Full Text] [Related]
10. [Infections during glucocorticoid use].
Minderhoud TC; van Meer MPA; van Thiel RJ; den Hoed CM; van Daele PLA; Schurink CAM
Ned Tijdschr Geneeskd; 2018 Aug; 162():. PubMed ID: 30212002
[TBL] [Abstract][Full Text] [Related]
11. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations.
Caplan A; Fett N; Rosenbach M; Werth VP; Micheletti RG
J Am Acad Dermatol; 2017 Feb; 76(2):191-198. PubMed ID: 28088990
[TBL] [Abstract][Full Text] [Related]
12. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.
Winthrop KL
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv29-30. PubMed ID: 16239382
[No Abstract] [Full Text] [Related]
13. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.
Park JW; Curtis JR; Moon J; Song YW; Kim S; Lee EB
Ann Rheum Dis; 2018 May; 77(5):644-649. PubMed ID: 29092853
[TBL] [Abstract][Full Text] [Related]
14. Does inhaled corticosteroid treatment result in a secondary immune deficiency predisposing to recurrent infections?
Bahceciler NN
Antiinflamm Antiallergy Agents Med Chem; 2012; 11(3):217-20. PubMed ID: 23061612
[TBL] [Abstract][Full Text] [Related]
15. Preventing and treating biologic-associated opportunistic infections.
Winthrop KL; Chiller T
Nat Rev Rheumatol; 2009 Jul; 5(7):405-10. PubMed ID: 19568254
[TBL] [Abstract][Full Text] [Related]
16. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.
Ma C; Walters B; Fedorak RN
World J Gastroenterol; 2013 Jun; 19(21):3347-51. PubMed ID: 23745038
[TBL] [Abstract][Full Text] [Related]
17. [Infections in patients affected by rheumatologic diseases associated to glucocorticoid use or tumor necrosis factor-alpha inhibitors].
Fica A
Rev Chilena Infectol; 2014 Apr; 31(2):181-95. PubMed ID: 24878907
[TBL] [Abstract][Full Text] [Related]
18. Infections associated with steroid use.
Klein NC; Go CH; Cunha BA
Infect Dis Clin North Am; 2001 Jun; 15(2):423-32, viii. PubMed ID: 11447704
[TBL] [Abstract][Full Text] [Related]
19. [Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 3. Opportunistic infections].
Sumida K; Ubara Y
Nihon Naika Gakkai Zasshi; 2013 Oct; 102(10):2631-8. PubMed ID: 24400544
[No Abstract] [Full Text] [Related]
20. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases.
Zhang Y; Zheng Y
Rheumatol Int; 2014 Dec; 34(12):1765-71. PubMed ID: 24948376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
